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ChangesintheBKvirusarchetypalnoncodingcontrolregion(NCCR)havebeenassociatedwithBK-virus-associatednephropathy
(BKVAN).Whethersustainedviremia,asurrogateforBKVAN,isassociatedwithsigniﬁcantchangesintheBK-NCCRisunknown.
We performed PCR ampliﬁcation and sequencing of (1) stored urine and (2) plasma samples from the time of peak viremia
from 11 patients with sustained viremia who participated in a 200-patient clinical trial. The antimetabolite was withdrawn for
BK viremia and reduction of the calcineurin inhibitor for sustained BK viremia. DNA sequencing from the 11 patients with
sustainedviremiarevealed 8insertions,16transversions,3deletions,and17transitions.Noneweredeemedsigniﬁcant.Nopatient
developed clinically evident BKVAN. Our data support, at a genomic level, the eﬀectiveness of reduction of immunosuppression
for prevention of progression from viremia to BKVAN.
1.Introduction
Human polyomavirus and associated infection were ﬁrst
identiﬁed in a urine sample of a transplant recipient with
ureteric stenosis in 1971 [1]. BK-virus-associated nephropa-
thy (BKVAN) was ﬁrst recognized in kidney transplant
recipients in 1995 [2]. The sequence of histopathologic
events is characterized by tubular necrosis, mixed interstitial
inﬂammatory inﬁltration, and ﬁnally, scarring and ﬁbrosis
of the renal interstitium [3]. BKV nephropathy currently
aﬀects 1–7% of recipients and has been associated with a 10–
100% graft loss rate depending on the severity of histological
involvement [4, 5]. It is likely that the last stage of an
unchecked BKV infection begins as asymptomatic viruria,
progresses to sustained viremia, possibly associated with
subclinical nephritis, and culminates in overt nephropathy.
Thus,sustainedBKVdetectedinplasmapredictsprogression
to BKV-associated interstitial nephritis, or nephropathy [6].
JC virus and SV40 virus are other members of the family
Polyomaviridae [7] and share 75% and 70% homology,
respectively, with BKV. They have three general transcription
regions: the noncoding control region (NCCR); the early
codingregion,whichcodesforthesmallandlargeTantigens;
and the late coding region, which codes for the viral capsid
proteins VP-1, VP-2, and VP-3 [8]. A fourth region, the
agnogene, encodes for the agnoprotein. The agnoprotein has
recently been thought to play a role in replicative life-cycle
of polyomaviruses and also in the dysregulation of cellular
p r o c e s s e ss u c ha sc e l lc y c l ec o n t r o la n dD N Ar e p a i r[ 9, 10].
The NCCR consists of the origin of replication [11]a n d
the transcription control region and is arbitrarily classiﬁed2 Journal of Transplantation
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Figure 1: Diagram showing the archetypal wild type BK virus
structure. The O, P, Q, and R blocks represent the noncontrol
coding region (NCCR).
into O, P, Q, R, and S regions as an aid to visualize genetic
rearrangements [12, 13]( Figure 1). These sites control the
expression of the early genes, late genes, and the agnoprotein
[13, 14]. The NCCR also contains a number of transcription
factor binding sites involved in the regulation of viral
genes. These include Sp-1 (speciﬁcity protein 1), NF-1
(nuclear factor 1), and CRE (cyclic-AMP response element).
Additionally, promoter-enhancing sequences that control
viral replication and regulate cellular oncogenes (c-myc)a n d
the p53 tumor suppressor gene are found within the BKV
NCCR [11].
BKV contains a ﬁxed number of nucleotides per NCCR
region. The archetypal strain of BKV, WW, is described as
O142, P63, Q39, R63, and S63, where block O consists of
142 base pairs, block P with 63, and so on (Figure 2). Any
deviation from the archetypal sequence and/or structural
formula represents a genetic variation in the NCCR region.
Although BKV strains are genotypically classiﬁed based
on polymorphisms in the VP-1 region (genotypes I–IV),
based on the NCCR structure, BKV variants are classiﬁed
either as archetype or as rearranged forms [15]. Therefore,
BKV variants with rearranged NCCRs are not considered
unique strains. Initially, it was proposed that NCCR rear-
rangementsaroseasanadaptationofthevirustocellculture.
With the application of polymerase chain reaction (PCR)
technology, one can amplify and sequence the naturally
occurring NCCR from clinical specimens, to determine
whether a rearrangement has occurred. The archetypal BK-
NCCR structure is the most common form found in the
urine [16]. It has been suggested that in permissive cells
the virus replicates and gives rise to rearranged enhancers
[14, 17], which permit viral species to adjust to transcrip-
tion conditions within the cell [18]. This might explain
the occurrence of BKV variants in speciﬁc tissues and
under diﬀerentclinicalconditions; however,themechanisms
or pressures, such as immunosuppression, regulating the
rearrangement events are unclear. Although associations of
rearranged viral strains with greater replication propensity
have been described, most publications are based on very
small data sets [5, 7]. Relationships between genetic rear-
rangement, viral genotype, tissue tropism, geographic dis-
tribution, pathogenicity, and progression of disease remain
inadequately studied.
Inadditiontogenomicrearrangements,geneticvariation
in the BK-NCCR can arise from point mutations, deletions,
and duplications of the basic sequence elements and can
aﬀect the transcriptional, transformational, and replicative
potential of the BKV variant [13]. Functional promoter
analysis and computational approaches have identiﬁed a
number of transcription factor binding sites within the BK-
NCCRs, such as a CRE within the P block, two SP-1 binding
elements within the Q and R blocks, and four NF-1 binding
sites within the P, Q, R, and S blocks [13]. Although the
coding region of the BKV genome is highly conserved,
minimal variations in the late region encoding the major
viral capsid protein VP-1 allow BKV to be divided into four
genotypes (I–IV).
A variety of genomic rearrangements have been detected
in the NCCR of the related human polyomavirus, for
example,JCvirustakenfromthebraintissueofpatientswith
progressive multifocal leukoencephalopathy (PML). These
rearrangementsseemtobecrucialinpermittingviralreplica-
tion in the brain and the lysis of oligodendrocytes [11]. This
is gaining increased clinical relevance given the increased
incidence and Black Box warnings regarding progressive
multifocal leukoencephalopathy (PML) associated with the
use of mycophenolate mofetil and Belatacept.
The association of BKV subtypes with clinical condi-
tions only recently has been described [19]. One study
demonstrated that BKV subtype I was predominant in
urine samples from bone marrow transplant recipients with
hemorrhagic cystitis. Other potential viral determinants of
hemorrhagic cystitis included overrepresentation of cytosine
(C) to guanosine (G) mutations in the NCCR SP-1 binding
site, limited to 7 of 13 patients with hemorrhagic cystitis.
However,thesealterationswerenotassociatedwithincreased
urinaryBKVloads,arguingagainstthepathogenicityofthese
variants [20].
A number of BKV-DNA sequence variants have been de-
scribed in the form of point mutations (transitions and
transversions), duplications, deletions, and rearrangements
localized to the NCCR of the viral DNA in renal trans-
plant patients, but they were not associated with disease.
Boldorini et al., however, reported the presence of NCCR
rearrangement in 3 of 5 (60%) biopsies with BKVAN [11].
Although they concluded that the NCCR rearrangements
did not necessarily correlate with the stage of BKVAN,
the presence of rearrangements in the majority of BKVAN
samples suggests a pathogenic role of rearrangement in
progression of BK virus infection. Similarly, Olsen et al.
reported an incidence of rearrangement of NCCR region
in 50% of patients with BKVAN [21]. A study of 30 renal
transplant recipients with BK viremia did not show anyJournal of Transplantation 3
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Figure 2: Diagram showing the noncontrol coding region (NCCR) region and describing the nucleotide sequence of the O, P, Q, R, and S
blocks in diﬀerent colors.
changes in the NCCR region in the urine or plasma samples
with high titer viruria or viremia but none of these recipients
developed BKVAN [22].
Thus, studies evaluating the rearrangement or mutation
in the NCCR as a factor in the pathogenesis and virulence
o fB Kv i r u sh a v ei n v o l v e ds m a l ln u m b e r so fp a t i e n t sa n d
have not been deﬁnitive. The purpose of this study was to
determine whether the presence of NCCR rearrangements or
mutations in the urine and blood of patients with sustained
BK viremia, a surrogate of BKVAN, was associated with
progression from BK viruria.
2.MaterialsandMethods
2.1. Study Design. From December 2000 to October 2002,
200 de novo kidney transplant recipients were enrolled in
a prospective open label trial and randomized to receive
tacrolimus or cyclosporine in a 2:1 block-design fashion
stratiﬁed by race and gender as previously described [23].
Recipients were prospectively monitored for the develop-
ment of BK viruria, viremia, and nephropathy. Identiﬁcation
of BK viremia triggered discontinuation of the antimetabo-
lite component of the immunosuppressive regimen upon
detection of BK-viremia and reduction in the calcineurin
component upon detection of sustained viremia to prevent
progression of viremia to nephropathy. Clinical data and
frozen plasma and DNA samples collected during 1-year
of follow-up were analyzed based on the development of
BK viruria, any viremia, and sustained viremia, deﬁned as
≥2 consecutive BKV positive plasma samples spanning ≥3
weeks. For the purposes of this study we selected samples
from the eleven patients with sustained viremia (as deﬁned
hereinafter)aroundthetimeofpeakviralloadinblood.The
WashingtonUniversityHumanStudiesCommitteeapproved
the study, and all patients gave informed consent for the
initial and follow-up studies.
2.2. Sample Collection and Preparation. Samples consisted of
undiluted whole blood, plasma, and urine samples collected
before -transplant, weekly for 16 weeks, and at months 5,
6, 9, and 12. Samples were stored at −80◦C. We identiﬁed
11/200 (6%) of patients with sustained BK viremia and high
urine viral load in our cohort. We selected one urine and two
plasma samples from each patient near the time of highest
blood viral load as viremia correlates with tissue invasive
disease.
2.3. BKV PCR Detection. Established qualitative PCR for
detection of BKV DNA was used as previously described and4 Journal of Transplantation
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Figure 3: Gel electrophoresis showing the DNA-ladder on each end with the all urine samples (a) and plasma samples (b) with the DNA-
ladder on the left side showing similarity between of NCCR region size in each sample.
performedinadiagnosticclinicallaboratory[16,23].Brieﬂy,
DNA was extracted and puriﬁed from urine and plasma
using QIAamp spin columns (QIAGEN Inc., Valencia, CA)
accordingtothemanufacturer’sinstructions.ExtractedDNA
was tested for BK virus DNA by real-time PCR using
the Light Cycler System (Roche Diagnostics Corporation,
Indianapolis, IN) using the primers, Pep-1 AGT CTT TAG
GGT CTT CTA CC and Pep-2 GGT GCC AAC CTA
TGG AAC AG, which amplify a 176-basepair segment of
the BK virus large T-antigen gene [24]. BK virus-speciﬁc
hybridization probes 5-TTG CCA TGA AGA TAT GTT TGC
CAG TGA TGA FITC-3 and 5-LCRed640 GAA GCA ACA
GCA GAT TCT CA 3 (TIB Molbiol LLC, Adelphia, NJ)
were used for detection. These probes were designed to
detect BK virus without detection of the related polyoma
viruses, JC virus and SV-40. Reactions were carried out in
a2 0 µL volume that included 2µL of Roche Light Cycler
FastStart DNA Hybridization Probe 10× reaction mix and
2µL of sample DNA. The ﬁnal concentrations of other
components were 3.5mM MgCl2,0 . 5µMo fe a c hp ri m e ra n d
0.2µM of each probe. The reaction program consisted of
denaturation for 7 minutes at 95◦C followed by 45 cycles
of denaturation at 95◦C instantaneous, annealing at 52◦C
for 10 seconds, and extension at 75◦C for 7 seconds. Each
reaction included positive controls consisting of 1000copies
of BK virus plasmid DNA (ATCC 45026) obtained from
the American Type Culture Collection (ATCC, Manassas,
VA) and negative controls for ampliﬁcation and DNA
preparation. The sensitivity of the qualitative assay was 20–
5 0B Kv i r u sD N Ac o p i e sp e rr e a c t i o n .
2.4. BKV PCR Quantiﬁcation. BK-positive samples were
quantiﬁed by repeat real-time PCR analysis of aliquots of
extracted DNA that had been frozen at −80◦C, alongside
a standard curve of control BKV DNA (2 × 108,2×
106,2× 104,a n d2× 102). The standards were prepared
from a plasmid (pBKV [35-1]) that contains the entire
linearized BKV genome (ATCC 45026) and was quantiﬁed
by spectrophotometry. The coeﬃcient of variability for the
quantitativeBKVLightCyclerassayinourlaboratorywasless
than 6%. The lower limit of sensitivity of the quantitative
PCR assay is 10000copies/mL.
2.5. Ampliﬁcation and Sequencing of the BKV Noncoding
Control Region. Nested PCR was carried out using the
following protocol [25]. The ﬁrst round PCR with primers
NCCR 722R (5  to 3 ) TTTCCCGTCTACACTGTCTTCACC
and NCCR 128F (5  to 3 ) CCCAGGCAGCTCTTTCAAGG
ampliﬁed a 596-bp fragment of BKV, including the NCCR.
The nested PCR reaction used primers NCCR 596 R (5  to
3 )TGACAGCTGGCGCAGAACCandNCCR164F(5  to3 )
GCTCCATGGATTCTTCCCTGTTAAGC which ampliﬁed a
432bp fragment of the previous PCR product.
The DNA ampliﬁcation reactions were carried out in
100µL volumes with 10µL of patient or control DNA,
1.25µL of Taq DNA polymerase (Invitrogen, Carlsbad, CA),
1.25µLo fe a c hp r i m e r ,a n d5 µLo fP C Rb u ﬀer includ-
ing deoxynucleoside triphosphates. The DNA ampliﬁcation
reactions for the nested PCR were carried out in 100µL
volumes with 5µL of from the initial reaction product,
1.875µLofTaqDNApolymerase(Invitrogen,Carlsbad,CA),
1.875µL of each primer, and 7.5µLo fP C Rb u ﬀer including
deoxynucleoside triphosphates.
Thermal cycling comprised an initial hot start at 94◦C
for 3 minutes followed by 30 cycles of 68◦C for 45 seconds
and the ﬁnal step at 68◦C for 1 minute. The PCR products
were visualized on a UV transilluminator, followed by gel
electrophoresis in 2% agarose gels containing ethidium
bromide. The PCR products were puriﬁed using a MinElute
PCR puriﬁcation kit (Qiagen, Valencia, CA).
Single-band PCR products of both strands were
sequenced using BigDye Terminator DNA-sequencing tech-
niques (Applied Biosystems, Foster City, CA) using both the
forward and reverse primers of the nested PCR reaction and
thesequencingdatawereanalyzedusingVectorNTIsoftware
(Invitrogen, Carlsbad, CA) to obtain a consensus sequence
using both strands.
3. Results and Discussion
Our prior studies showed that BK virus DNA was detected
in urine samples from 70 recipients (35% of the 198 with
samples available for analysis) [23]. The estimated incidence
of BK viruria through 365 days after -transplant was 35%.
The baseline demographic characteristics did not aﬀect theJournal of Transplantation 5
Table 1: Basic demographic data of the patients and sample characteristics.
Patient
Viral load
µ Age Sex Type of
transplant∗∗ Race Underlying
diagnosis¶
Onset
of
viruria
Peak of
viruria
µ
Onset
of
viremia
Peak of
viremia
µ Mutation∗
Plasma Urine
Sample
1
Sample
2
1 5.79 5.29 10.24 59 M DDA White DM1, CIN Week 5 10.35 Week 9 5.79 P(1), D(0),
T(3), I(2)
2 5.46 5.32 11.34 76 M DDA African
American DM, HTN Week 9 11.67 Week
13 5.46 P(4), D(1),
T(3), I(0)
3 5.85 5.9 11.13 31 M DDA White PSGN,
FSGS Week 6 11.35 Week 7 5.9 P(2), D(0),
T(4), I(0)
4 5.24 5.6 8.32 59 M LRD White HTN Week 1 8.32 Week 5 5.6 P(0), D(1),
T(0), I(0)
5 5.35 5.68 8.79 65 M DDA White HTN Week 2 10.65 Week
13 5.68 P(2), D(0),
T(1), I(0)
6 2.5 2.5 12.02 49 M DDA African
American DM2, HTN Week 1 12.02 Week 4 2.5 P(4), D(0),
T(2), I(0)
7 5.53 5.26 no
Sample 59 M DDA White FSGS Month
9 10.15 Month
9 5.53 P(1), D(0),
T(2), I(0)
8 5 2.5 10.1 49 F DDA White MPGN, SLE Week 3 8.62 Week 5 5 P(2), D(0),
T(2), I(1)
9 5.52 5.36 9.65 48 F LURD White IGAN Week 1 9.65 Week 5 5.52 P(0), D(1),
T(0), I(0)
10 5.76 5.17 10.74 23 F DDA White Wegners Week 3 5.36 Week 7 5.76 P(0), D(0),
T(0), I(5)
11 5.76 5.59 10.67 59 M DDA White HTN Week 1 10.77 Week 4 6.04 P(0), D(0),
T(0), I(0)
∗I: insertion; P: transversions; D: deletion; T: transitions.
∗∗LRD: living related transplant; DDA: deceased donor allograft, LURD: living un related donor transplant.
µ :l o g 10
¶DM2: type 2 Diabetes Mellitus; HTN: hypertension; FSGS: focal segmental glomerulosclerosis; PSGN: post streptococcal glomerulonephritis; IGAN: IgA
Nephropathy; MPGN: membranoproliferative glomerulonephritis; SLE: systemic Lupus Erythematosus.
incidence of BK viruria. BK viremia was detected in 23
patients. BK viremia never occurred in the absence of viruria
and followed or was contemporaneous with BK viruria. The
overall estimated incidence of viremia was 12% through 365
days. Sustained BK viremia was detected in 11 (6%) patients.
No clinically evident BKVAN was seen by 12 months, and
none had been seen at the last date of observation.
We anticipated a total of 33 samples with BK viruria
available for analysis. However, one patient had insuﬃcient
DNA in the urine sample to allow for further ampliﬁcation,
and we were not able to amplify the BK virus in one of the
plasma samples in two patients and in both plasma samples
in one patient. Thus, we had 28 complete NCCR sequences
to analyze.
Among the 11 patients with sustained viremia, the
mean viral load in the plasma samples was 5.08 log10
copies/mL (range 2.5Log10–5.90log10 copies/mL), with a
median of 5.49log10 copies/mL. The mean viral load in
the urine samples was 10.3log10 copies/mL (range 8.32
log10–12.02log10 copies/mL), with a median of 10.17
log10 copies/mL.
G i v e nt h em a g n i t u d eo fo u rv i r a ll o a dw ee x p e c t e dt o
ﬁndsigniﬁcantrearrangements,thatis,theadditionofwhole
blocks in the NCCR regions of the ampliﬁcation product.
We initially evaluated the size of the product and compared
this to our control. We did not ﬁnd any signiﬁcant change
when compared to control (ATCC 45026). Only two of
our plasma samples showed two diﬀerent bands on gel
electrophoresis which were only 25bp diﬀerent from the
control suggesting that there might be smaller mutations
in our samples (Figure 3). Thus, we further examined our
products after DNA sequencing to assess for small changes
in the sequence. We compared our sequence results with the
wild type NCCR reported in the literature [18].
We only found small changes in the BK virus genome
(Table 1). In total, we found 8 insertions, 16 transversions,
3 deletions, and 17 transitions. We deﬁned transitions
as a pyrimidine nucleotide replacing a pyrimidine and a
transversions as a replacement of pyrimidine with a purine
or vice versa. Deletion and insertion were deﬁned as a
removal or addition of a nucleotide. However, no signiﬁcant
rearrangements or sequence variations such as duplications
or inversions were identiﬁed. No changes were noted in the
aforementioned Sp-1, CRE, or NF-1 sites.
The pathogenesis of BK virus infection is not clearly un-
derstood. Based on observation studies, it is thought that6 Journal of Transplantation
BK virus infection occurs due to the failure in the balance
between BK virus replication and natural immunological
control of that process resulting in BKVAN. In addition
to host factors, it is hypothesized that various viral factors
contribute to the pathogenesis of BKVAN. To date all studies
looking at these factors have been uncontrolled and small
and only suggestive of the possibility of a viral determinant
of BKVAN [26].
It has been reported that BKV variants with rearranged
NCCR are present in immunocompromised patients with
kidney transplants [18, 21, 26]. In a retrospective analysis of
matched urine and plasma samples from patients with any
BK viremia of which 70 had BKVAN, Gosert et al. reported
that rearranged NCCR variant BKV replaced the wild type in
24%ofkidneytransplantpatientswithpersistentBKviremia
and in 50% of patients with BKVAN [5]. BK virus with
rearranged NCCR had a 20-fold higher median viral load
and higher probability of histologically conﬁrmed disease
when compared to wild type NCCR BKV. Rearranged NCCR
was detectable in patients with peak viral load of 6.5log10
genome equivalents(geq)/mL for <4 months, whereas a 100-
fold lower viremia required >7 times longer times suggesting
that the duration and higher peak viral load favored the
change from the wild type, ww-NCCR, to rearranged, rr-
NCCR, as a majority species. They conﬁrmed the role of
rearrangements in the NCCR and polyomavirus nephropa-
thy in a prospective cohort of 73 plasma samples from 227
kidney transplant recipients of which 39 had BKVAN. The
role of rearranged NCCR was further conﬁrmed in elegant
in vitro studies using a novel bidirectional reporter replicon
that mimics polyoma replication.
Their patients were not in a clinical trial and no system-
atic intervention such as reduction in immunosuppression
was used for clinical management of viremia. Our patients
were in a clinical trial, and since we promptly reduced
immunosuppression upon detection of viremia, none of our
patients developed very high viral loads (peak viral load of
5.90log10copies/mL) for more than a month. Thus, our
study supports the ﬁndings of Gosert et al. and explains the
absence of rearranged NCCR in our samples.
Bressollette-Bodin et al. reported results showing that
NCCR mutation or rearrangement was not present in
patients with viremia or viruria [22]. It is unclear from
their data whether they had sustained viremia or viruria.
The number of samples with high titer viremia and viruria
was lower than that of our patients and BKVAN was not
observed. It is unclear whether this was due to the fact that
their immunosuppression regimen was diﬀerent than ours
including a prednisone-free regimen and their follow-up was
foronlyayear.Thusitcannotbeconcludedifandwhentheir
patientsdevelopedBKVANandwhethertheNCCRmutation
may have occurred.
We found only minor changes in the NCCR region
associated with sustained viremia. We did not observe
any clinically evident BKV nephropathy. Thus, we could
not determine whether changes in the BK-NCCR region
might be associated with progression from sustained BK-
viremia to BKVAN. Signiﬁcantly, the peak viral load in our
patients was lower than that in the study by Gosert et
al. perhaps as a consequence of our clinical management
of immunosuppressive reduction upon detection of BK-
viremia [5]. Our interventional strategy of withdrawal of the
antimetaboliteandfurtherreductioninimmunosuppression
with persistence of sustained viremia may have removed the
selective pressure that would have led to rearrangements and
subsequent development of BKVAN. There may also be a
threshold of viral load that may determine tissue invasive
disease, that is, a higher load being suggestive of aggressive
disease with mutation or pathogenetic rearrangements in the
NCCR.
The major limitation of this study is that there was no
clinically evident BKVN; hence it cannot be assumed that
if it had occurred, it may have resulted from changes in the
NCCR. Given the serious impact of BK viremia, we felt that
it was unethical simply to follow the patients without inter-
vention. Our strategy was successful in the short and long
term and resulted in excellent clinical outcomes [16, 23, 27].
The current study provides translational and mechanistic
support, at a genomic level, for our interventional approach.
Although the sample size, n = 11, of patients with sustained
viremia, a surrogate of BKVAN, is small, it is the largest such
assessment to date looking at whether NCCR arrangements
are associated with sustained viremia.
4. Conclusion
Sustained viremia in our study in association with sig-
niﬁcant immunosuppression withdrawal upon detection
of BK viremia was not associated with rearrangement
and/or sequence variation in the NCCR region of the BK
virus. Our ﬁndings do not exclude the possibility of an
association between transition from sustained BK viremia
to BKVAN based on NCCR rearrangement or sequence
variation. Our data, however, support the eﬀectiveness of a
clinicalinterventionalapproachofwithdrawalandreduction
of immunosuppression upon detection of sustained BK-
viremiaforpreventionofprogressionfromsustainedviremia
to BKVAN that may have removed the immunosuppressive
selective pressure for mutation of the virus that may have led
to progression of disease.
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